Neuropathy Progression in Variant Transthyretin Amyloidosis: Comparison Between TTR Stabilizers and Gene Silencer Therapies
- 15 September 2026
- journal article
- Published by Wiley in Muscle & Nerve
- Vol. 74 (6) , 1546-1553
Abstract
Introduction/Aims: Transthyretin ( TTR ) stabilizers and gene‐silencing therapies are approved for hereditary transthyretin‐mediated amyloidosis with polyneuropathy ( ATTRv ‐ PN ), but data from clinical practice in patients who transition between therapies due to disease progression remains limited. The primary aim of this study is to evaluate the effectiveness of patisiran in ATTRv ‐ PN patients who progressed despite prior treatment with tafamidis 20 mg. Methods: We conducted a retrospective multicenter observational study including patients with ATTRV30M (p.V50M) with polyneuropathy who were initially treated with tafamidis 20 mg and subsequently switched to patisiran due to documented neuropathy progression. Patients had at least 12 months of follow‐up under each treatment. Neuropathy progression was assessed using the Neuropathy Impairment Score (NIS), neurophysiological composite scores, nutritional status, serum biomarkers, and patient‐reported outcomes. Results: Thirty‐two patients (mean age 52 ± 14 years; mean disease onset 43 ± 23.5 years) were included. Median disease duration before treatment initiation was 1.8 ± 1.9 years. The mean duration of tafamidis and patisiran treatment was 4.5 ± 2.8 and 2.5 ± 2.3 years, respectively. The annual increase in NIS was significantly lower during patisiran treatment than during tafamidis (0.7 ± 3.9 vs. 3.9 ± 4.7; p = 0.004). Decline in neurophysiological parameters slowed after switching. Discussion: In this cohort, patisiran attenuated neuropathy progression in patients who had deteriorated despite tafamidis. These findings highlight the importance of ongoing clinical monitoring to guide timely treatment optimization.Keywords
This publication has 38 references indexed in Scilit:
- Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA Neurology, 2025
- Patisiran in ATTRv amyloidosis with polyneuropathy: “PatisiranItaly” multicenter observational studyJournal of Neurology, 2025
- Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in ItalyNeurological Sciences, 2024
- A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in BelgiumActa Neurologica Belgica, 2023
- A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes SurveyNeurology and Therapy, 2021
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathyJournal of Neurology, 2020
- Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological studyJournal of Neurology, 2016
- Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaJournal of Neurology, 2016
- Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisNeurology and Therapy, 2016
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 2013